CAS 1173204-81-3 PKI-402 PI3K Inhibitors Inhibited Cell Growth
CAS 1173204-81-3 PKI-402 PI3K Inhibitors Inhibited Cell Growth
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:PKI-402 |
Purity:98% min |
|
CAS NO:1173204-81-3 |
Solubility:DMSO< 1 mg/mL |
|
Molecular Formula:C29H34N10O3 |
Package:Package according to customer requirements |
|
Molecular Weight:570.645 |
Storage:Store at -20℃ |
Quality control
Remarks
PKI-402 is a selective, reversible, ATP-competitive, equipotent inhibitor of class I phosphatidylinositol 3-kinases (PI3K), including PI3K-alpha mutants, and mammalian target of rapamycin (mTOR; IC(50) versus PI3K-alpha = 2 nmol/L). PKI-402 inhibited growth of human tumor cell lines derived from breast, brain (glioma), pancreas, and non-small cell lung cancer tissue and suppressed phosphorylation of PI3K and mTOR effector proteins (e.g., Akt at T308) at concentrations that matched those that inhibited cell growth.
Related Products:
Voxtalisib; Pilaralisib; PI-3065; VS-5584; PIK-294; AZD6482; GSK1059615; AZD8186; CUDC-907; AZD8835; AMG319; Buparlisib hydrochloride; Umbralisib; PIK-III; VPS34-IN1; VPS34 inhibitor 1; Wortmannin
References
[1].Mallon R et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.